{"id":996074,"date":"2026-08-17T11:24:37","date_gmt":"2026-08-17T15:24:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/repl-deadline-levi-korsinsky-reminds-replimune-group-inc-investors-of-upcoming-securities-class-action-deadline\/"},"modified":"2026-08-17T11:24:37","modified_gmt":"2026-08-17T15:24:37","slug":"repl-deadline-levi-korsinsky-reminds-replimune-group-inc-investors-of-upcoming-securities-class-action-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repl-deadline-levi-korsinsky-reminds-replimune-group-inc-investors-of-upcoming-securities-class-action-deadline\/","title":{"rendered":"REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline"},"content":{"rendered":"

\nAlert: Replimune shares collapsed from a $10.73 Class Period high to $1.70 following the FDA’s rejection of the RP1 biologics license application, a cumulative decline of roughly 84% that the complaint alleges followed disclosures correcting earlier statements about the resubmission.
\n<\/h2>\n
\n

NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action filed on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026. Find out if you may qualify to recover losses<\/u><\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/u><\/a> or (212) 363-7500.<\/p>\n

REPL closed at a Class Period high of $10.73 on December 8, 2025. On April 10, 2026, shares fell $1.15, or 19.46%, to $4.76 before trading was halted. On the next trading day, April 13, 2026, shares fell another $3.06, or 64.29%, to close at $1.70 \u2014 a cumulative decline of approximately $9.03 per share, or 84.16%, from the Class Period high. Investors have until October 5, 2026 to seek lead plaintiff status.<\/p>\n

\n The Two-Day Market Repricing of REPL<\/strong>\n <\/p>\n

Both trading sessions occurred on unusually heavy volume, according to the filing. The first leg followed the FDA’s publication, during market hours, of a Complete Response Letter rejecting the biologics license application for RP1 in combination with nivolumab. The second leg followed an after-market press release the same day in which the Company acknowledged that the FDA had preferred a randomized controlled trial.<\/p>\n

\n What the Market Reaction Reflected, as Alleged<\/strong>\n <\/p>\n

As set forth in the complaint, the FDA stated that its study design concerns had been “clearly communicated” in multiple interactions and that those concerns “were not addressed.” The agency also stated that the resubmission relied on data from an early unplanned analysis representing 10% of planned enrollment, and that this data was “insufficient to support an efficacy claim.” It is alleged that shareholders purchased at prices that did not reflect these conditions.<\/p>\n

\n Alleged Investor Harm by the Numbers<\/strong>\n <\/p>\n